LiveRamp Faces Investor Lawsuit Over Proposed Publicis Sale

What happened

Shareholder rights law firm Johnson Fistel is investigating LiveRamp's board for potential fiduciary duty breaches in the proposed sale to Publicis Groupe, casting doubt on whether the deal adequately values the company. The investigation comes as LiveRamp's ARR growth has slowed to 7% and subscription net retention slipped to 102%, though the company maintains strong cash flow and a net cash balance sheet. Our master report had already rated the stock a WAIT with a base case value of $28 per share, noting that current pricing around $24 embeds only modest growth expectations. The lawsuit introduces a binary outcome: if the board is forced to seek a higher price or the deal collapses, shares could re-rate based on stand-alone prospects. Conversely, if the deal closes at the current terms, investors may receive a premium, but the investigation raises the risk of delay or renegotiation.

Implication

For long-term investors, the lawsuit could lead to a higher acquisition price if the board is pressured to shop around, potentially unlocking value above the current stand-alone thesis. However, if the deal collapses, LiveRamp returns to a decelerating growth story with limited catalysts, making our $18 bear case more plausible. Monitor for announcements of higher bids or deal termination; in the meantime, the stock's risk-reward is skewed to the downside given the uncertainty and weak underlying growth metrics.

Thesis delta

The introduction of a shareholder lawsuit over the Publicis deal shifts the thesis from a wait-for-organic-growth-reacceleration to a binary event around the acquisition. Previously, the call hinged on ARR and retention metrics improving over 6–12 months; now, the primary driver is whether the deal closes at a premium or fails, with organic growth acting as a floor. We maintain our WAIT rating but lower conviction given the added legal risk and potential for deal-related volatility.